Work

Supplementary Table S3 from Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

Year: 2023

Type: supplementary-materials

Abstract: Maximum % cytotoxicity and phagocytosis and EC50 values for CLDN18.2-307-mAb in HUPT4 cels

DOI: 10.1158/1535-7163.24709933

Authors: Neil A. O'Brien, Martina S.J. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M. Madrid, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4389242209

Cites:

Cited by:

Related to: 10